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Suppression of PPARγ-mediated 
monoacylglycerol O-acyltransferase 
1 expression ameliorates alcoholic 
hepatic steatosis
Jung Hwan Yu1,2, Su Jin Song1,2, Ara Kim1,2, Yoonjeong Choi1,2, Jo Woon Seok1,2, 
Hyo Jung Kim1, Yoo Jeong Lee3, Kwan Sik Lee4 & Jae-woo Kim1,2,5
Alcohol consumption is one of the major causes of hepatic steatosis, fibrosis, cirrhosis, and 
superimposed hepatocellular carcinoma. Ethanol metabolism alters the NAD+/NADH ratio, thereby 
suppressing the activity of sirtuin family proteins, which may affect lipid metabolism in liver cells. 
However, it is not clear how long-term ingestion of ethanol eventually causes lipid accumulation in 
liver. Here, we demonstrate that chronic ethanol ingestion activates peroxisome proliferator-activated 
receptor γ (PPARγ) and its target gene, monoacylglycerol O-acyltransferase 1 (MGAT1). During ethanol 
metabolism, a low NAD+/NADH ratio repressed NAD-dependent deacetylase sirtuin 1 (SIRT1) activity, 
concomitantly resulting in increased acetylated PPARγ with high transcriptional activity. Accordingly, 
SIRT1 transgenic mice exhibited a low level of acetylated PPARγ and were protected from hepatic 
steatosis driven by alcohol or PPARγ2 overexpression, suggesting that ethanol metabolism causes lipid 
accumulation through activation of PPARγ through acetylation. Among the genes induced by PPARγ 
upon alcohol consumption, MGAT1 has been shown to be involved in triglyceride synthesis. Thus, we 
tested the effect of MGAT1 knockdown in mice following ethanol consumption, and found a significant 
reduction in alcohol-induced hepatic lipid accumulation. These results suggest that MGAT1 may afford a 
promising approach to the treatment of fatty liver disease.
Alcoholic liver disease, which is a major cause of morbidity and mortality worldwide, is associated with increased 
cardiovascular disease and diabetes1. Accumulation of fat in the liver in response to alcohol consumption can 
lead to more harmful forms of liver disease such as fibrosis, cirrhosis, and end-stage liver injury. Despite numer-
ous studies on the pathogenesis of alcoholic liver diseases, targeted therapies based on the mechanism by which 
alcohol consumption causes hepatic steatosis are unavailable. The spectrum of alcoholic liver disease ranges 
from simple steatosis to more serious injury including cirrhosis. Because fatty liver damage is reversible when 
detected early, the best way to resolve this alcohol-mediated liver damage at this stage is abstaining from alcohol2. 
However, in order to provide improved, more effective therapies, elucidation of the mechanism by which ethanol 
metabolism causes lipid accumulation in the liver is required.
Recent studies indicate that ethanol increases fatty acid synthesis in hepatocytes by regulating lipid 
metabolism-associated transcription factors such as sterol regulatory element-binding protein 1c (SREBP1c) 
and carbohydrate-responsive element-binding protein (ChREBP), which promote fatty acid synthesis via 
up-regulation of lipogenic genes3. While ethanol is metabolized in liver, alcohol dehydrogenase and aldehydro-
genase catalyze the conversion of NAD+ to NADH, thereby reducing the NAD+/NADH ratio similar to the fed 
state, in which the glycolysis pathway is activated and, in turn, sirtuin 1 (SIRT1) is inactivated4. SIRT1 is an 
NAD-dependent deacetylase that is activated in response to fasting, caloric restriction, and physical exercise5. 
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This enzyme plays an important role in hepatic lipid metabolism by modulating the acetylation of transcription 
factors such as peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α )6. Recent research 
reveals that SIRT1 signaling is also associated with alcoholic liver disease as SIRT1 stimulation protects against 
alcohol-induced liver damage6,7. Because ethanol metabolism mimics the fed state even in the absence of glu-
cose in terms of the NAD+/NADH ratio, these studies suggest that ethanol metabolism affects lipid metabolism 
through SIRT1 activity.
In adipocytes, SIRT1 represses peroxisome proliferator-activated receptor γ (PPARγ ) activity by recruiting 
a co-repressor, which results in fat mobilization8. Others have reported that SIRT1 directly deacetylates PPARγ 
, promoting brown remodeling of white adipocytes9. Thus, one of the mechanisms by which SIRT1 modulates 
hepatic lipid metabolism may involve PPARγ , a master regulator of lipid metabolism10,11. Among the two iso-
forms, PPARγ 2 is mainly present in adipose tissue, intestines, and macrophages to regulate fatty acid storage 
and glucose metabolism. In normal liver, PPARγ expression remains low. However, its expression is increased 
in a mouse model of obesity and plays a critical role in hepatic steatosis by regulating the expression of lipogenic 
genes12. In addition, hepatic PPARγ expression is associated with triglyceride (TG) synthesis and lipid accumula-
tion13,14. Recently, we reported that increased PPARγ 2 expression is a major contributor to high-fat-diet-induced 
hepatic steatosis, demonstrating that monoacylglycerol O-acyltransferase 1 (MGAT1), a PPARγ -regulated 
enzyme, plays a critical role in lipid accumulation15.
MGAT1 is an enzyme that catalyzes the synthesis of diacylglycerol from monoacylglycerol and fatty acyl 
CoA. Thus, MGAT1 contributes to lipid accumulation via an alternative pathway for TG synthesis16. MGAT1, 
along with PPARγ , is expressed at low levels in normal liver but is highly up-regulated in diet-induced hepatic 
steatosis15. In this regard, inhibiting MGAT1 expression eventually suppressed hepatic lipid accumulation, as 
demonstrated by several studies in which MGAT1 is knocked down by adenovirus-mediated small hairpin RNA 
(shRNA)15, antisense oligonucleotides17, and liver-specific non-viral small interfering RNA (siRNA)18. Although 
these studies are restricted to non-alcoholic hepatic steatosis, we hypothesize that PPARγ and its downstream 
effector MGAT1 may play a role in alcohol-induced hepatic lipid accumulation if SIRT1 affects hepatic PPARγ 
during ethanol metabolism.
In this study, we found that PPARγ is activated in alcohol-induced hepatic steatosis and associated with reduc-
ing SIRT1 activity upon ethanol metabolism. Furthermore, our data suggest that inhibition of MGAT1 efficiently 
attenuated lipid accumulation due to alcohol consumption in liver. Therefore, we suggest that PPARγ is an impor-
tant regulator of ethanol-induced hepatic steatosis, and that the development of an MGAT1 inhibitor could be an 
effective therapy for treating alcoholic or non-alcoholic hepatic steatosis.
Results
Ethanol decreased the NAD+/NADH ratio and SIRT1 activity. To study the effects of alcohol metab-
olism, we used C57BL/6 (B6) mice, which are widely used in metabolic disease research. Male B6 mice were 
pair-fed a Liber-Decarli liquid diet with or without (27% of total calories) ethanol for 4 weeks (Fig. 1a). Exposure 
to an ethanol diet for 4 weeks resulted in a significant increase in hepatic TG content and liver weight, indi-
cating that ethanol-induced hepatic steatosis and increased liver weight (Fig. 1b,c; oil-red-O staining shown 
in Supplementary Fig. S1). Notably, the NAD+/NADH ratio was significantly decreased in ethanol-fed mice 
(Fig. 1c). The level of SIRT1, an NAD-dependent deacetylase, also decreased, while PPARγ was not remarkably 
changed (Fig. 1d). However, acetylation of PPARγ clearly increased in ethanol-fed mice (Fig. 1e), suggesting that 
the SIRT1 activity required to deacetylate PPARγ is suppressed upon ethanol feeding. Increased PPARγ acetyl-
ation resulted in marked up-regulation of its target genes, including MGAT1, CD36, and G0s2, while PPARγ 
mRNA increased slightly (Fig. 1f). Another transcription factor known to play an important role in the patho-
physiology of alcoholic hepatic steatosis, SREBP1c, was also highly expressed along with its target genes, which 
include liver-type pyruvate kinase (L-PK), stearyl CoA desaturase 1 (SCD1), glycerol phosphate acyltransferase 
(GPAT), fatty acid elongase 6 (Elvol6), and fatty acid synthase (FAS) (Fig. 1f). These data indicate that the fatty 
acid de novo synthesis pathway is also elevated following alcohol ingestion.
The mRNA levels of the seven known types of sirtuins revealed that expression of all sirtuin types was reduced 
in the alcohol-fed group (Supplementary Fig. S2). Of these, we checked the relationship between SIRT1 and 
ethanol-induced lipid metabolism, mainly focused on PPARγ activity. Further studies may be required to explore 
the linkage between alcohol metabolism and other sirtuins such as sirtuin 3 and 6, which are known to be 
involved in body metabolism.
SIRT1 protects the liver from alcohol-induced hepatic steatosis. Next, we used SIRT1 transgenic 
mice to evaluate its role in ethanol metabolism. Wildtype and SIRT1 transgenic mice were pair-fed a Liber-Decarli 
liquid diet with ethanol (27% of total calories) for 4 weeks. While wildtype mice developed a significant accumu-
lation of lipid in the liver, SIRT1 transgenic mice displayed a protective effect on ethanol-induced hepatic steatosis 
(Fig. 2a; oil-red-O staining shown in Supplementary Fig. S1). Throughout the experimental period, food intake 
was similar and ethanol feeding had no apparent effect on the health status of both mouse groups. Although body 
weight remained unchanged, the liver weights were lower in SIRT1 transgenic mice (Fig. 2b). Liver TG content in 
these mice was also decreased significantly compared to wildtype animals (Fig. 2b). The level of PPARγ protein 
did not differ significantly in SIRT1 transgenic mice (Fig. 2c), but acetylation of PPARγ appeared to decrease 
(Fig. 2d). Furthermore, the expression of PPARγ and its target genes, including MGAT1, aP2/422, and CD36, was 
also reduced (Fig. 2e). These data suggest that PPARγ activity, with subsequent PPARγ expression, also decreased. 
The levels of aspartate transaminase (AST) and alanine transaminase (ALT), which are indicators of liver inflam-
mation, were also decreased in SIRT1 transgenic mice (Fig. 2f).
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Because these transgenic mice express SIRT1 throughout the body, we could not rule out effects from other 
organs such as adipose tissue. To examine the effect of SIRT1 on hepatic lipid accumulation directly, we employed 
adenoviruses as vectors to express SIRT1 because they preferentially target the liver in mice19. During etha-
nol feeding, adenovirus overexpressing GFP or SIRT1 was injected into the tail vein 2 weeks before the end 
of the experimental period (Fig. 3a). This administration led to robust expression of hepatic SIRT1 (Fig. 3b), 
which attenuated ethanol-induced hepatic lipid accumulation (Fig. 3c,d). Interestingly, liver weight was similar 
with this short-term expression of SIRT1 (Fig. 3d). SIRT1 overexpression in the liver caused down-regulation 
of PPARγ and its target gene, MGAT1 (Fig. 3e), suggesting that ethanol metabolism eventually affects lipid 
metabolism through SIRT1. Taken together, these data indicate that SIRT1 has a protective and beneficial role in 
alcohol-induced hepatic steatosis.
SIRT1 attenuates PPARγ2-induced hepatic steatosis. We demonstrated that SIRT1 overexpression 
attenuates ethanol-induced hepatic steatosis, in which PPARγ acetylation is decreased. To verify the involvement 
of PPARγ in SIRT1-mediated effects on the fatty liver, we administered adenoviral PPARγ 2 (Ad-PPARγ 2) into 
wildtype or SIRT1 transgenic mice via tail vein injection (Fig. 4a). As reported previously15, Ad-PPARγ 2 injec-
tion produced severe hepatic steatosis (Fig. 4b; oil-red-O staining shown in Supplementary Fig. S1) with higher 
levels of hepatic TG than control Ad-GFP mice (Fig. 4c). Histological analysis revealed the presence of numerous 
fat droplets in the liver of Ad-PPARγ 2-injected mice. However, SIRT1 transgenic mice overexpressing PPARγ 2 
exhibited lower levels of hepatic TG than wildtype mice (Fig. 4b,c). Ad-PPARγ 2 injection induced the expression 
Figure 1. Ethanol decreases the NAD+/NADH ratio and SIRT1 activity to cause PPARγ acetylation.  
(a) Schedule of ethanol and control diet regimens. (b) H&E staining performed on liver sections from mice.  
(c) Hepatic TG and cholesterol content, liver weight, serum aspartate transaminase (AST) alanine transaminase 
(ALT) levels, and NAD+/NADH ratio in the livers of control diet and ethanol diet-fed mice. (n = 6 per group) 
(d) Western blot analysis of SIRT1, PPARγ , and β -actin. (n = 5 per group) (e) PPARγ acetylation in control and 
ethanol diet-fed mice. (n = 3 per group) (f) Expression of PPARγ and SREBP1c and their target genes in control 
and ethanol diet-fed mice. (n = 6–8 per group) Data represent the mean ± SD. * P < 0.05, * * P < 0.01.
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Figure 2. SIRT1 transgenic mice exert a protective effect on alcohol-induced hepatic steatosis. (a) H&E 
staining performed on liver sections from mice. (b) Body weight, liver weight, hepatic TG, and cholesterol in 
wild type and SIRT1 transgenic mice. (c) Western blot analysis of SIRT1, PPARγ , and β -actin. (n = 5 per group) 
(d) PPARγ acetylation in wild type and SIRT1 transgenic mice. (n = 3 per group) (e) Real-time PCR analysis of 
PPARγ and its target genes in liver. (f) AST and ALT levels in blood samples. (n = 6 per group). Data represent 
the mean ± SD. * P < 0.05, * * P < 0.01.
Figure 3. The effect of SIRT1 overexpression via adenovirus injection on alcohol-induced hepatic steatosis. 
(a) Schedule of SIRT1 adenovirus injection. Ad-SIRT1 or Ad-GFP was introduced via tail vein injection at 
2 weeks after initiation of ethanol feeding. The mice were sacrificed 2 weeks later. (b) Western blot analysis 
showing SIRT1 expression in the liver of Ad-GFP- and Ad-SIRT1-injected mice. (c) H&E staining performed on 
liver sections from mice. (d) Body weight, liver weight, hepatic TG, and cholesterol content. (e) Real-time PCR 
analysis of PPARγ and MGAT1 expression. (n = 5) Data represent the mean ± SD. * P < 0.05.
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of several PPARγ targets and lipogenic genes. However, this increase in gene expression was attenuated in SIRT1 
transgenic mice (Fig. 4d).
We also analyzed the effect of PPARγ 2 overexpression in primary mouse hepatocytes. These cells were sub-
jected to immunocytochemistry to detect adipose differentiation-related protein (ADRP), which is a target gene 
of PPARγ that localizes to the lipid droplet. PPARγ 2 overexpression resulted in increased ADRP expression in 
primary hepatocytes; however, this increase was significantly attenuated in cells isolated from SIRT1 transgenic 
mice (Fig. 4e). These results suggest that PPARγ acts as a major regulator in hepatic TG synthesis and SIRT1 
inhibits PPARγ -induced hepatic steatosis.
MGAT1 knockdown protects against alcohol-induced hepatic steatosis. Previously, we 
reported that knockdown of PPARγ -regulated MGAT1 expression can successfully improve diet-induced 
non-alcoholic hepatic steatosis in murine and human models15,20. Our results shown here strongly suggest 
that the PPARγ -MGAT1 axis contributes to the development and aggravation of lipid accumulation both in 
non-alcoholic and alcoholic hepatic steatosis. However, the mechanism of PPARγ activation might be different. 
To examine whether MGAT1 suppression can reduce ethanol-induced hepatic steatosis, male B6 mice were fed a 
Liber-Decarli liquid diet with or without ethanol (27% of total calories) for 3 weeks and then administered with 
adenoviral sh-control or sh-MGAT1 via tail vein injection. After 1 week of continued diet, mice were sacrificed 
for analysis (Fig. 5a). As shown in Fig. 5b (oil-red-O staining shown in Supplementary Fig. S1), knockdown of 
Figure 4. The effect of PPARγ2 overexpression on wild type and SIRT1 transgenic mice. (a) Schedule of 
PPARγ 2 overexpression. Wild type and SIRT1 transgenic mice were injected with Ad-PPARγ 2 or an Ad-GFP 
via the tail vein, fed a chow diet for 1 week, and then sacrificed. (b) H&E staining performed on liver sections of 
wild type and SIRT1 transgenic mice. (c) Hepatic TG content in wild type and SIRT1 transgenic mice infected 
with Ad-GFP or Ad-PPARγ 2. (d) Real-time PCR analysis of PPARγ target genes and lipogenic genes in wild 
type and SIRT1 transgenic mice. (e) Immunofluorescence staining for adipose differentiation-related protein 
(ADRP, green) in mouse primary hepatocytes. Nuclei were stained with DAPI and fluorescence was visualized 
by confocal microscopy. Scale bar = 50 μ m. Data in c and d represent the mean ± SD. * P < 0.05, * * P < 0.01.
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hepatic MGAT1 significantly improved ethanol-induced hepatic steatosis. The hepatic TG level was reduced by 
42% after only 1 week of MGAT1 knockdown (Fig. 5c). Furthermore, hepatic MGAT1 knockdown also resulted 
in decreased liver weight, suggesting that MGAT1 expression plays an important role in alcohol-induced hepatic 
steatosis (Fig. 5c). Targeting MGAT1 did not affect the expression of PPARγ and its other regulatory genes such 
as aP2/422 and CD36, suggesting that MGAT1 is a critical factor involved in the accumulation of hepatic lipid 
upon ethanol feeding (Fig. 5d).
To verify the role of the SIRT1-PPARγ -MGAT1 axis in this process, we tested MGAT1 mRNA expression 
in the presence of PPARγ and/or SIRT1. As shown in Fig. 5e, SIRT1 efficiently suppressed PPARγ 2-induced 
MGAT1 expression. Nicotinamide (NA), a known SIRT1 inhibitor, counteracted the suppressive effects of SIRT1. 
Luciferase assays also showed that SIRT1 suppresses PPARγ 2-induced MGAT1 promoter activity in human 
hepatoma-derived HepG2 cells (Fig. 5f). To evaluate whether SREBP1c, another major transcription regulator of 
hepatic steatosis, regulates MGAT expression, we overexpressed SREBP1c into human HepG2 cells. Our data show 
that SREBP1c did not affect the expression level of all three MGAT subtypes in human cells (Supplementary Fig. S3), 
suggesting that increased SREBP1c and PPARγ during ethanol feeding contributes to lipid accumulation via 
distinct mechanisms.
A previous study reported that PPARγ acetylation sites (lysine residues 98, 107, 218, 268, and 293) were 
affected by SIRT19. Therefore, we generated various PPARγ 2 mutant forms (K98R, K107R, K218R, K268R, and 
Figure 5. MGAT1 knockdown suppresses alcohol-induced hepatic steatosis. (a) Schedule of MGAT1 
knockdown in ethanol-fed mice. Adenoviral sh-control or sh-MGAT1 was introduced via tail vein injection 
at 3 weeks after initiation of ethanol feeding. One week later, the mice were sacrificed. (b) H&E staining 
performed on liver sections from mice in paired, ethanol-fed with sh-control, and ethanol-fed with sh-MGAT1 
groups. (c) Body weight, liver weight, hepatic TG, and cholesterol content. (d) Real-time PCR analysis showing 
the expression of PPARγ and its target genes. (n = 6). Data represent the mean ± SD. * P < 0.05. (e) Primary 
hepatocytes (4 × 105 cells per well) cultured on 6-well plates were infected with 50 MOI of Ad-GFP, Ad-PPARγ 
2, and Ad-SIRT1 with or without nicotinamide (NA, 10 μ M). MGAT1 mRNA was analyzed by real-time PCR. 
(f) Luciferase assay using human MGAT1 promoters (~2 kb) was performed. In HepG2 cells, MGAT1 promoter 
constructs were co-transfected with or without PPARγ 2/RXRα overexpression vectors along with 100 MOI of 
either Ad-GFP or Ad-SIRT1. Data represent the mean ± SD from three independent experiments performed in 
duplicate. * P < 0.05, * * P < 0.01.
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K293R) to evaluate the role of the acetylation sites in modulating PPARγ -induced MGAT1 expression. However, 
as shown in Supplementary Fig. S4, we could not find a significant difference in PPARγ activity following muta-
tion of the acetylation sites, which regulate MGAT1 expression. This result suggests that MGAT1 expression is 
regulated by acetylation on other sites or combination of various acetylation.
Ethanol metabolism in binge drinking. Binge drinking is the act of consuming heavy amounts of alco-
hol in a short time period. Recently, the role of ChREBP in binge drinking was reported3. In this report, acute 
alcohol consumption affected the activity of ChREBP by regulating its acetylation. Based on this finding, we 
explored the role of PPARγ and the early response to alcohol consumption through a binge drinking mouse 
model. Twelve-week-old male C57BL/6J mice were fasted for 4 h before receiving two doses of gavages with 
equivalent calories of DM or ethanol at 3.5 g/kg (Fig. 6a). Examination of these animals revealed that the NAD+/
NADH ratio was decreased in the binge drinking group compared to the DM group (Fig. 6b). The SIRT1 level 
was also decreased after binge drinking (Fig. 6c). PPARγ expression and its acetylation were increased with 
binge drinking (Fig. 6d,e). Also, the level of SREBP1c and ChREBP mRNA was increased in the livers of the 
ethanol-consuming group (Fig. 6e). Accordingly, the expression of SREBP1c and ChREBP target genes such as 
SCD1, L-PK, and FAS increased; however, expression of PPARγ target genes remained at a low level (Fig. 6f). 
These results suggest that the expression level of PPARγ in this setting was not sufficient to induce its target 
genes even though PPARγ mRNA was up-regulated by two-fold. Thus, we hypothesize that binge drinking 
initially affects SREBP1c or ChREBP to develop a mild steatosis primarily by fatty acid de novo synthesis, which 
later induces a sufficient level of acetylated PPARγ and its target genes, and ultimately aggravating hepatic 
steatosis (Fig. 7).
Discussion
Excessive alcohol consumption is an important public health problem that contributes substantially to the global 
burden of mortality and morbidity. In the 2010 Global Burden of Disease study, alcohol-attributable liver disease 
was responsible for 493,300 deaths (156,900 females and 336,400 males) representing 0.9% of all global deaths21. 
Therefore, efforts to reduce alcohol consumption and prevent alcohol-induced hepatic damage are needed. 
Alcoholic liver disease starts with hepatic steatosis, which is characterized by an increase in intrahepatic TG. 
Continuous alcohol consumption leads to hepatic inflammation and liver fibrosis. Studies estimate that a third of 
patients with steatosis will develop hepatic inflammation and 8% to 20% of patients with steatosis will eventually 
progress to cirrhosis1. The main causes for alcoholic fatty liver are known to be accumulation of acetaldehyde, 
tumor necrosis factor α , endoplasmic reticulum stress, 2-arachidonoylgycerol, and adenosine, which increase 
SREBP1c activity and induce fatty acid synthesis, leading to alcoholic fatty liver. Other transcription factors also 
contribute to the pathogenesis of alcoholic liver disease. For example, PPARα , another major regulator, decreases 
fatty acid β -oxidation1. Recently, ChREBP was reported to play a role during the early period of alcohol consump-
tion3. On the other hand, hepatic PPARγ , which is known as a critical regulator of TG accumulation in adipose 
tissue, has yet to be investigated in alcohol-induced hepatic steatosis until now.
A ligand-activated transcription factor, PPARγ is a member of the nuclear receptor superfamily that primarily 
regulates adipogenesis and lipid accumulation22. Because PPARγ expression in the liver is low compared to that in 
adipose tissue, the role of this transcription factor in the liver remains controversial13. In the past decade, studies 
found that hepatic PPARγ is significantly increased in an obese animal model and plays an important role in fatty 
liver formation23,24. In our study, alcohol-fed mice appeared to exhibit an increase in hepatic PPARγ protein to a 
certain extent; however, comparison to control mice nullified any apparent increase. However, the expression of 
PPARγ target genes increased in alcohol-fed mice. Therefore, we investigated the post-translational modification 
of PPARγ to examine how ethanol regulates PPARγ activity. Studies have demonstrated that PPARγ function 
is regulated by several post-translational modifications, including phosphorylation, acetylation, sumoylation, 
and ubiquitination24,25. PPARγ is phosphorylated within the AF1 region by mitogen-activated protein kinases or 
cyclin-dependent kinases (Cdk7 and Cdk9), which regulate PPARγ activity in opposing manners26. Moreover, 
it was found that PPARγ is phosphorylated within the ligand binding domain at Ser273 by Cdk5 to control 
the expression of a distinct group of genes that becomes deregulated in obesity27. Sumoylation of PPARγ in the 
AF1 region represses its transcriptional activity, possibly by recruiting a co-repressor28. Additionally, PPARγ has 
been shown to be ubiquitinated, which is enhanced by ligand binding like thiazolidinediones29. The regulation 
of PPARγ function by acetylation has not been extensively studied; however, it is evident that PPARγ activity is 
associated with acetylation as PPARγ activity is attenuated by the presence of a deacetylase such as HDAC3 and 
SIRT130.
SIRT1 regulates lipid metabolism by deacetylating lysine residues on transcription factors such as SREBP1c 
and PGC1α in liver31,32. However, the mechanism by which SIRT1 regulates hepatic PPARγ function, especially 
in alcoholic fatty liver, remains poorly understood. In this study, we established that SIRT1 is involved in alcoholic 
hepatic steatosis by regulating the acetylation of PPARγ and its activity. We also observed that PPARγ overex-
pression could induce hepatic steatosis, and that knockdown of MGAT1, a PPARγ target gene, could inhibit 
hepatic lipid accumulation. We previously showed that MGAT1 is a direct target gene of PPARγ , by identifying 
functional PPAR-response element in the promoter15, and also reported that human MGAT1 is also regulated 
by PPARγ shown by luciferase assay20. Therefore, we propose that the PPARγ signaling pathway is critical in 
hepatic lipid synthesis and fatty liver formation. In order to examine whether other pathways may involve in 
the regulation of MGAT1 in ethanol feeding, we also investigated SREBP1c, which is reported to play a role in 
alcoholic hepatic steatosis. Supplementary Fig. S3, however, showed that the expression of MGAT genes did 
not change in response to SREBP1c overexpression. In addition, it is noteworthy that MGAT1 was not induced 
upon binge drinking shown in Fig. 6, where SREBP1c and ChREBP are highly expressed. Thus, it is unlikely that 
SREBP1c or ChREBP regulates MGAT1. Nevertheless, it is still possible that other pathways in ethanol feeding 
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regulate MGAT1, because the short-term binge drinking could not activate the MGAT1 transcription even in the 
induction of PPARγ and its acetylation (Fig. 6). It may be due to the lack of lipid signaling required for PPARγ 
transcriptional activity, but we cannot rule out the involvement of other pathways.
The causes of hepatic steatosis have been categorized as either alcoholic or non-alcoholic. Despite this, it 
is difficult to differentiate between these types of hepatic steatosis in the clinic. Furthermore, alcohol syner-
gistically increases the prevalence and severity of hepatic steatosis in obese patients33,34. Discovering similar 
pathways between non-alcoholic and alcoholic hepatic steatosis is a useful strategy for developing effective 
therapeutics for treating hepatic steatosis. In this study, we identified that the SIRT1-PPARγ -MGAT1 axis is 
critically involved in alcoholic hepatic steatosis, making MGAT1 a potential therapeutic target of hepatic fatty 
liver disease.
Figure 6. Ethanol metabolism in binge drinking leads to the activation of SREBP1c and ChREBP.  
(a) Schedule of binge drinking experiment. B6 mice were fasted for 4 h before receiving two gavages of equivalent 
calories of ethanol at 3.5 g/kg or dextrin-maltose (DM). Mice were sacrificed 6 h later. (b) NAD+/NADH ratio 
examined in DM and ethanol-fed mice group. (n = 6 per group) (c) Western blot analysis showing SIRT1 expression 
in DM and ethanol-fed mice group. (n = 4 per group) (d) PPARγ acetylation in DM and ethanol-fed mice group. 
(n = 3 per group) (e,f) Real-time PCR analysis showing expression of PPARγ , SREBP1c, ChREBP, and their target 
genes. (n = 6). Data represent the mean ± SD. * * P < 0.01.
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Materials and Methods
Mice and diet. Male C57BL/6J mice were purchased from SLC (Japan). The animals were maintained in 
a temperature-controlled room (22 °C) on a 12:12-h light–dark cycle. Mice (at 7 or 8 weeks of age) were fed a 
Lieber-DeCarli liquid diet (Dyets) containing 1 Kcal/ml, of which 18% was derived from protein, 35% of fat, and 
either 47% from carbohydrate (control diet) or 20% from carbohydrate and 27% from ethanol (alcohol diet) for 
up to 4 weeks. Ethanol was introduced gradually by increasing the content by 9% of its total caloric-intake until 
the mice were consuming a diet containing 27% ethanol, which was then continued for three more weeks. Mice 
were paired-fed, and body weight and food intake were monitored daily. Body weight was measured once a week. 
Adenovirus injection (2 × 109 pfu) through the tail vein was administered at weeks 2 or 3 of the liquid diet period 
to suit each experiment. At the end of the experiment, mice were sacrificed and liver tissues and blood samples 
were collected. Male SIRT1 transgenic mice were purchased from Jackson Laboratory (Bar Harbor, ME). Binge 
drinking was modeled using a modified version of a recently published protocol3. Briefly, twelve-week-old male 
C57BL/6J mice were fasted for 4 h before receiving two gavages of equivalent calories of ethanol at 3.5 g/kg or 
dextrin-maltose (DM; MP Biomedicals, Santa Ana, CA). Mice were kept on a heating pad for the duration of the 
experiment to prevent hypothermia. Then, mice were sacrificed 6 h later. Liver tissues were fixed with 10% (vol/vol) 
formalin and embedded in paraffin, and were stained with H&E or oil-red-O. All experimental protocols involv-
ing animals, including maintenance and care, were performed in accordance with the National Institutes of 
Health guidelines and ethics guidelines of Yonsei University, and all animal procedures were approved by the 
Committee on Animal Investigations of Yonsei University.
RNA isolation and analysis of gene expression by quantitative RT-PCR. Total RNA was 
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
First-strand cDNA synthesis from 5 μ g total RNA was performed using SuperScript III reverse transcriptase 
(Invitrogen) primed with random hexamer primers. Real-time qPCR was performed using SYBR Green 
Master mix (Applied Biosystems) with a Step One instrument (Applied Biosystems, Foster City, CA). 
Figure 7. Model of alcohol-induced hepatic steatosis. During ethanol digestion, NAD+ is converted into 
NADH by alcohol dehydrogenase and aldehyde dehydrogenase. A low NAD+/NADH ratio represses NAD-
dependent deacetylase sirtuin 1 (SIRT1) activity. Reduced SIRT1 activity causes the activation of SREBP1c, 
ChREBP, and PPARγ . In the early phase, expression of SREBP1c and ChREBP target genes, such as L-PK, FAS, 
and SCD1, are increased, and then PPARγ target genes including MGAT1 are increased. Expression of PPARγ 
and its target genes lead to the development of alcoholic steatosis.
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Expression of Rplp0 was also measured as an invariant control. The primer sequences used in real-time 
qPCR are as follows: PPARγ , 5′ -CTCTGGGAGATTCTCCTGTT-3′, 5′-GGTGGGCCAGAATGGCATCT-3′; 
SREBP1c, 5′-GGAGCCATGGATTGCACATT-3′, 5′-GGCCCGGGAAGTCACTGT-3′; ChREBP, 5′-CCTC 
ACTTCACTGTGCCTCA-3′, 5′-ACAGGGGTTGTTGTCTCTGG-3′; aP2/422, 5′-TCTCCAGTGAAAA 
CTTCGAT-3′, 5′-TACGCTGATGATCATGTTG-3′ ; FSP27, 5′-TCCAGGACATCTTGAAACTT-3′, 
5′-GGCTTGCAAGTATTCTTCTG T-3′; Cd36, 5′-TGCACCACATATCTACCAAA-3′, 5′-TTGTAACCCCAC 
AAGAGTTC-3′; FAS, 5′-AAGCC GTTGGGAGTGAAAGT-3′, 5′-CAATCTGGATGGCAGTGAGG-3′; MGAT1, 
5′-CTGGTTCTGTTTCCCGTTGT-3′, 5′-TGGGTCAAGGCCATCTTAAC-3′; L-PK, 5′-CCGAGATACGC 
ACTGGAGTC-3′, 5′-GTGGTAGTCCACCCACACTG-3′; SCD1, 5′-TTCTCAGAAACACACGCCGA-3′, 
5′-AGCTTCTCGGCTTTCAGGTC-3′; GPAT, 5′-TCCTAGCTCGCGATTTCGAC-3′, 5′-ATCTTTCCTG 
CTCGTGTGGG-3′; Elovl6, 5′-TGCTGATGGGCTGTGTCATT-3′, 5′-GGAGTAGCACTGGTCGTTGT-3′; G0S2, 
5′-AAAGTGTGCAGGAGCTGATC-3′, 5′-GGACTGCTGTTCACACGCTT-3′ and Rplp0, 5′-GCAGGTGTTT 
GACAACGGCA G-3′, 5′-GATGATGGAGTGTGGCACCG A-3′ .
Western blot analysis. For protein preparation from liver tissues, mouse livers (50 mg) were placed in a 
glass homogenizer containing 1 ml Pro-Prep Protein Extraction Solution (Intron Biotechnology, Korea). Tissue 
lysates were separated by SDS-PAGE. Primary antibodies against SIRT1, PPARγ (Santa Cruz Biotechnology, 
Santa Cruz, CA), acetylated lysine (Cell Signaling Technology, Danvers, MA), and β -actin were used. Bands 
were detected with anti-rabbit or anti-mouse IgG conjugated with horseradish peroxidase (Pierce) using the 
ECL-PLUS detection system (Amersham, Little Chalfont, UK).
Primary hepatocyte culture. Primary mouse hepatocytes were isolated using the two-step collagenase 
perfusion method from the livers of male C57BL/6 (8 weeks old) mice as previously described35. Hepatocytes 
were plated onto six-well dishes at 1.0 × 106 cells per well and incubated for 12 h in DMEM containing 10% 
FBS to allow cells to attach. Cell counts and viability (Adam cell counter; Digital Bio) were confirmed before 
use. Viability was routinely > 85%. After attachment, cells were infected with PPARγ 2- and SIRT1-expressing 
adenoviruses.
Preparation of recombinant adenovirus. Murine PPARγ 2 and SIRT1 cDNAs were cloned into the 
pcDNA3 or FLAG-tagged pcDNA3 vectors, respectively. Recombinant adenovirus (Ad) expressing PPARγ 2 and 
ad-shRNA for MGAT1 were prepared as described15. All viruses were propagated in 293A cells and purified by 
CsCl density purification, dissolved in 1x HBSS (Invitrogen), and stored at − 70 °C. The multiplicity of infection 
(MOI) was calculated from viral particle numbers. Recombinant adenovirus containing the GFP gene or Ad-US 
control RNAi were used as controls.
TG and cholesterol assay in the liver. Liver extracts (from 0.2 g tissues) were prepared by homogeniza-
tion in chloroform:methanol (2:1, v/v). TG and cholesterol levels were measured using TG assay or cholesterol 
assay reagents (ThermoFisher Scientific, Waltham, MA). The TG level was calculated from measurements of the 
absorbance at 500 nM and expressed as mg TG/g liver wet weight.
Transfection and luciferase assay. HepG2 cells were transfected with the pGL3-MGATs promoter plas-
mid15,20 as indicated or pRL-CMV (Promega, Madison, WI) using Lipofectamine (Invitrogen) according to the 
manufacturer’s instructions. After 24 h, luciferase activity was measured using the Dual Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s instructions. Firefly luciferase activities were standardized to 
Renilla activities.
NAD+/NADH assay. The NAD+/NADH ratio was measured using NAD/NADH assay kits from Abcam 
according to the manufacturer’s instructions. Absorbance was measured at 450 nm using the multi-detection 
reader (VERSA max, Molecular Devices, Sunnyvale, CA).
Immunoprecipitation and PPARγ acetylation. For immunoprecipitation, we lysed tissues using a pas-
sive lysis buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 
and protease inhibitor cocktail). Proteins were immunoprecipitated with anti-PPARγ antibody (Santa Cruz 
Biotechnology), collected with protein A/G conjugated agarose beads (Santa Cruz Biotechnology), and washed 
three times with lysis buffer. Acetylation of immunoprecipitated proteins was assessed using anti-acetylated lysine 
antibody (Cell Signaling Technology). Western blots for PPARγ were also performed to assess the total protein 
quantity.
Immunocytochemistry. Primary mouse hepatocytes were isolated from the livers of wildtype or SIRT1 
transgenic mice (10 weeks old, male) and then transfected with Ad-GFP or Ad-PPARγ 2. At the indicated times, 
cells were washed with PBS, fixed in 4% formaldehyde for 15 min, permeabilized with 0.2% Triton X-100 for 20 min 
on ice, and then blocked in 3% bovine serum albumin in PBS for 1 h. Cells were then incubated in a blocking 
solution containing ADRP antibody (1:200 dilution) for 12 h, followed by fluorescein isothiocyanate-conjugated 
anti-mouse IgG secondary antibody for 2 h. The cells were mounted in 4′ ,6-diamidino-2-phenylindole. Cells were 
then visualized with a Confocal Laser Scanning Microscope (Olympus FV1000).
Statistical analysis. All data are expressed as the mean ± SD with n representing the number of analyzed 
mice. Statistical significance of observed differences between groups was determined using the unpaired Student’s 
t-test. P < 0.05 was considered as statistically significant.
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